Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma

REFERENCES

• Zweegman S., Huijgens P. C. Treatment of myeloma: recent developments. Anticancer Drugs 2002; 13(4)339–351
   PubMed Web of Science ®Google Scholar
• Cooper M. R., Dear K., McIntyre R., Ozer H., Ellerton J., et al. A randomized clinical trial comparing melphalan/prednisolone with or without interferon alfa-2b in newly diagnosed patients with multiple myeloma: a Cancer and Leukemia Group B study. J. Clin. Oncol. 1993; 11(1)155–160
   PubMed Web of Science ®Google Scholar
• Osterborg A., Bjorkholm M., Bjoreman M., Brenning G., Carlson K., et al. Natural interferon-alpha in combination with melphalan/prednisolone versus melphalan/prednisolone in the treatment of multiple myeloma stages II and III: a randomized study from the Myeloma Group of Central Sweden. Blood 1993; 81(6)1428–1434
   PubMed Web of Science ®Google Scholar
• Ludwig H., Cohen A. M., Polliack A., Huber H., Nachbaur D., et al. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicentre randomized trials and summary of other studies. Ann. Oncol. 1995; 6(5)467–476
   PubMed Web of Science ®Google Scholar
• Salmon S. E., Crowley J. J., Grogan T. M., Finley P., Pugh R. P., Barlogie B. Combination chemotherapy, glucocorticoids, and Interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. J. Clin. Oncol. 1994; 12(11)2405–2414
   PubMed Web of Science ®Google Scholar
• Gisslinger H. Interferon alpha in the therapy of multiple myleoma. Leukemia 1997; 11: S52–56, (Suppl. 5)
   PubMed Web of Science ®Google Scholar
• Kars A., Celik I., Kansu E., Tekuzman G., Ozisik Y., et al. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma. Eur. J. Haematol. 1997; 59(2)100–104
   PubMed Web of Science ®Google Scholar
• Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N. Engl. J. Med. 1999; 341(21)1565–1571
   PubMed Web of Science ®Google Scholar
• Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet 1999; 354(9182)925
   PubMed Web of Science ®Google Scholar
• Strasser K., Ludwig H. Thalidomode treatment in multiple myeloma. Blood Rev. 2002; 16(4)207–215
   PubMed Web of Science ®Google Scholar
• Rajkumar S. V. Thalidomide in multiple myeloma. Oncology (Williston Park) 2000; 14: 11–16, (13 Suppl. 13)
   PubMed Web of Science ®Google Scholar
• Bauer J. A., Morrison B. H., Grane R. W., Jacobs B. S., Borden E. C., Lindner D. J. IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J. Interferon Cytokine Res. 2003; 23(1)3–10
   PubMed Web of Science ®Google Scholar
• Moher D., Schulz K. F., Altman D. G., for the CONSORT Group. The CONSORT Statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann. Intern. Med. 2001; 134(8)657–662
   PubMed Web of Science ®Google Scholar
• Altman D. G., Schulz K. F., Moher D., Egger M., Davidoff F., Elbourne D., Gotzsche P. C., Lang T., for the CONSORT Group. The revised CONSRT Statement for reporting randomized trials: explanation and elaboration. Ann. Intern. Med. 2001; 134(8)663–694
   PubMed Web of Science ®Google Scholar
• Kasper B., Moehler T., Neben K., Ho A. D., Goldschmidt H. Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma. Ann. Oncol. 2004; 15(1)176–177
   PubMed Web of Science ®Google Scholar
• Nathan P. D., Gore M. E., Eisen T. G. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J. Clin. Oncol. 2002; 20(5)1429–1430
   PubMed Web of Science ®Google Scholar
• Clark P. E., Hall M. C., Miller A., Ridenhour K. P., Stindt D., Lovato J. F., et al. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 2004; 63(6)1061–1065
   PubMed Web of Science ®Google Scholar
• Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N. Engl. J. Med. 1990; 322(20)1430–1434
   PubMed Web of Science ®Google Scholar
• Westin J., Rodjer S., Turesson I., Cortelezzi A., Hjorth M., Zador G. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: a randomized study Cooperative Study Group. Br. J. Haematol. 1995; 89(3)561–568
   PubMed Web of Science ®Google Scholar
• Drayson M. T., Chapman C. E., Dunn J. A., Olujohungbe A. B., Maclennan I. C. MRC trial of alfa-2b-interferon maintenance therapy in first plateau phase of multiple myeloma. Br. J. Haematol. 1998; 101(1)195–202
   PubMed Web of Science ®Google Scholar